Immuno-oncology innovations redefining cancer treatment in 2024
Drug Target Review
JANUARY 23, 2024
In April 2023, we saw the first randomised data applying an individualised vaccine in combination with checkpoint inhibition for resectable melanoma, demonstrating benefit in terms of time to disease recurrence. Espen integrates clinical and research expertise as Director of Medical Affairs.
Let's personalize your content